


COVID-19

Vaccine Update



Consonus now has bamlanivimab infusion in all pharmacies and is ready to accept orders!

Consonus Healthcare first informed you of the emergency use approval (EUA) of bamlanivimab on November 17th with a FAQ and a little humor on how to pronounce it. We now have allocation of this product in each pharmacy and are eager to be a resource for those navigating COVID-19 outbreaks. Monoclonal antibody therapy in high-risk patients may reduce the length of symptoms and lessen likelihood of hospitalization.

As your trusted pharmacy partner, we continue to work diligently to ensure all our customers gain access to the COVID-19 vaccine and to keep you updated on treatments through the complex and rapidly changing situation.

Q: When should bamlanivimab be administered to a patient?

A: It is recommended that bamlanivimab be administered as soon as possible after positive viral test for SARS-CoV-2 and within 10 days of symptom onset. Bamlanivimab is administered as a single dose of 700 mg via IV infusion over 60 minutes.

Q: Who might benefit from bamlanivimab?

A: Patients in skilled nursing facilities with mild to moderate COVID-19 symptoms that are at high-risk, such as those that are at least 65 years old or overweight or have other health conditions. Bamlanivimab is authorized to treat OUTPATIENTS with COVID-19. It is not indicated for hospitalized patients.

Q: Which healthcare facilities are eligible to receive bamlanivimab for administration?


A: This infusion is ideal for nursing facilities that handle IVs and have adequate healthcare staffing to safely administer and monitor the therapy (up to 3 hours). Settings should have immediate access to medications to treat a severe infusion reaction, or the rare event of anaphylaxis. The Medical Director should be engaged to provide physician oversight and careful supervision of the medication administration, to ensure that adverse reactions can be minimized, and residents kept safe.

Q: How can the facility order bamlanivimab?

A: The process will work similarly to ordering and receiving other intravenous medications. We recommend you call the pharmacy to discuss any clinical or medication administration questions.

COVID-19

Vaccine Update



Q: What is the cost of bamlanivimab therapy?

A: It is currently provided at no charge to the pharmacy so we will not bill the facility for the infusion medication. The IV Supplies will also be provided at no charge to the facility. There are costs involved in compounding, supplies, delivery, data tracking and monitoring. Therefore, Consonus is working on proper billing scenarios to Medicare, Medicaid and Commercial insurance plans depending on the payor source of the recipient.

Q: Can the COVID-19 vaccine be administered to persons who previously received monoclonal antibody therapy for COVID-19?

A: The COVID-19 vaccine should be deferred until 90 days after the administration of monoclonal antibody treatment to avoid interference of the treatment with vaccine-induced immune responses.

Q: Where do I find more information on patients that are at risk or important safety information?

A: Please refer to the EUA requirements and Fact Sheet for healthcare providers for more information. Patients or responsible party must be given the EUA fact sheet specific to patients and caregivers and have risks and benefits explained.

<https://www.fda.gov/media/143603/download>

Other resources:

ASCP/AMDA Readiness packet and Lilly Playbook:

<https://cdn.ymaws.com/www.ascp.com/resource/resmgr/docs/mab/fulldocument2.pdf>

<https://www.covid19.lilly.com/assets/pdf/bamlanivimab/lilly-antibodies-playbook.pdf>